TGEN Tecogen Inc

Targeted Genetics Corporation (Nasdaq:TGEN) today announced that its President and CEO, H. Stewart Parker, and Executive Vice President and Chief Scientific Officer, Barrie J. Carter, Ph.D., will participate in panel discussions as part of the BIO 2006 Annual International Convention, McCormick Place, Chicago, IL. Ms. Parker will serve as a panelist on a BIO Ethics panel for the Biotechnology Institute titled, "What does the Future of Biotech Hold for Us? Issues of Ethics, Justice and Medicine," to be held, Saturday, April 8, at 3:30 p.m., Palmer House Hilton, Chicago. The panel will discuss and debate whether bioethics should be taught or addressed through legislation, bioethics considerations for multiethnic research and clinical trial design, and how corporations and the industry are affected. Dr. Carter will serve as a panelist on a Clinical Research/Clinical Trials session titled, "Procedural and Substantive Issues in Oversight of Gene Transfer Research: IRB Review, IBC Review and Ethics," to be held on Monday, April 10 at 2:00 p.m., McCormick Place, Room 404A. The panel will discuss and debate the issues that arise in gene transfer clinical interventions, the history and current view of the ethical issues and current procedural issues in coordinating oversight of gene transfer research, federal and local regulations and guidelines, biosafety and ethical issues. About Targeted Genetics Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements regarding our business strategy, our product development and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, enrollment of patients, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in Item 1A. Risk Factors in our report on Form 10-K for the year ended December 31, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.